The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice
Viruses · 2024
DOI: 10.3390/v16060989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Anna Ivanina und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia. Hauptthemen laut MEDLINE: Herpesvirus 1, Human, Herpesvirus 2, Human, Antiviral Agents, Herpes Genitalis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: OOO Firn M.
Abstract (Originalsprache)
Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are widespread human pathogens that establish chronic latent infections leading to recurrent episodes. Current treatments are limited, necessitating the development of novel antiviral strategies. This study aimed to assess the antiviral efficacy of novel topical formulations containing interferon alpha-2b (IFN α-2b) against HSV-1 and HSV-2. The formulations, Oftalmoferon® forte (eye drops) and Interferon Vaginal Tablets, demonstrated potent antiviral effects against HSV-1 and HSV-2 in Vero cells, respectively, with concentration-dependent inhibition of viral replication. Subsequently, their efficacy was tested in animal models: HSV-1 keratitis in the rabbit eye model and HSV-2 genital herpes in mice. Oftalmoferon® forte effectively treated HSV-1 keratitis, reducing clinical symptoms and ulcerations compared to virus control. Interferon Vaginal Tablets showed promising results in controlling HSV-2 genital herpes in mice, improving survival rates, reducing clinical signs, weight loss and viral replication. The novel IFN α-2b formulations exhibited significant antiviral activity against HSV infections in cell culture and animal models. These findings suggest the potential of these formulations as alternative treatments for HSV infections, particularly in cases resistant to current therapies. Further studies are warranted to optimize treatment regimens and assess clinical efficacy in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mechnikov Research Institute of Vaccines and Sera, Department of Virology, 105064 Moscow, Russia.
- OOO Firn M, Biotech Company, 108804 Moscow, Russia.
ORCID-Profile: Anna Ivanina, Irina Falynskova, Ekaterina Glubokova, Nadezhda Kartashova, Nadezda Pankova, Sergei Korovkin
Förderung
- OOO Firn M
Zitieren
APA
Ivanina, A., Leneva, I., Falynskova, I., Glubokova, E., Kartashova, N., Pankova, N., Korovkin, S., & Svitich, O. (2024). The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice. Viruses. https://doi.org/10.3390/v16060989
Vancouver
Ivanina A, Leneva I, Falynskova I, Glubokova E, Kartashova N, Pankova N, et al. The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice. Viruses. 2024. doi:10.3390/v16060989
BibTeX
@article{Ivanina2024,
author = {Ivanina, Anna and Leneva, Irina and Falynskova, Irina and Glubokova, Ekaterina and Kartashova, Nadezhda and Pankova, Nadezda and Korovkin, Sergei and Svitich, Oxana},
title = {The Topical Novel Formulations of Interferon α-2в Effectively Inhibit HSV-1 Keratitis in the Rabbit Eye Model and HSV-2 Genital Herpes in Mice},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16060989}
}
EUVIMED